2/20/2020 1:19:08 PM
AbbVie (ABBV) Declares Quarterly Dividend of $ 1.18, Record Date 4/15/2020
2/13/2020 6:07:09 AM
AbbVie Says Nova Scotia Lists SKYRIZI On Its Provincial Formulary For Treatment Of Moderate To Severe Plaque Psoriasis
2/7/2020 7:44:41 AM
AbbVie Q4 EPS $1.88 On GAAP Basis; Adjusted EPS $2.21
2/6/2020 6:04:42 AM
AbbVie Says SKYRIZI Now Publicly Reimbursed In Ontario, Alberta, Saskatchewan And Quebec
2/5/2020 8:46:40 AM
AbbVie Says RINVOQ Meets Primary And Key Secondary Endpoints In Phase 3 Study In Psoriatic Arthritis
1/31/2020 7:18:58 AM
AbbVie Gets Positive CHMP Opinion For MAVIRET
1/31/2020 6:58:17 AM
AbbVie Gets Positive CHMP Opinion For VENCLYXTO As ChemotherapyFree Combination Regimen For Chronic Lymphocytic Leukemia
1/27/2020 8:19:12 AM
AbbVie Reports Extension Of Expiration Date For Exchange Offers For Allergan Notes To February 28, 2020
1/27/2020 1:17:00 AM
Allergan Enters Definitive Agreements To Divest Brazikumab And Zenpep
1/14/2020 8:48:49 AM
AbbVie : SKYRIZI Meets Both Primary And All Secondary Endpoints In Head-to-head, Open-label Study Versus Cosentyx
1/14/2020 5:33:52 AM
AbbVie Says MAVIRET Is Now Listed On The Newfoundland And Labrador Formulary